Takeda Pharmaceutical Co Ltd ADR TAK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
-
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
-
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
-
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
-
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
-
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
-
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
-
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
Trading Information
- Previous Close Price
- $19.93
- Day Range
- $20.08–20.39
- 52-Week Range
- $12.99–20.39
- Bid/Ask
- $19.60 / $20.40
- Shares Outstanding
- 3.19B
- Market Cap
- $65.04B
- Volume/Avg
- 4,000 / 3M
Key Statistics
- Price/Earnings (Normalized)
- 52.90
- Price/Sales
- 2.15
- Dividend Yield (Trailing)
- 3.10%
- Dividend Yield (Forward)
- 3.03%
- Dividend Payment Schedule
- Jul, Dec
- Total Yield
- 3.63%
Company Profile
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 47,029
- Website
- https://www.takeda.com
Competitors
Valuation
|
Metric
|
TAK
|
4568
|
4519
|
|---|---|---|---|
Price/Earnings (Normalized) | 52.90 | 20.50 | 22.67 |
Price/Book Value | 1.38 | 3.03 | 5.37 |
Price/Sales | 2.15 | 2.35 | 8.11 |
Price/Cash Flow | 12.02 | 79.62 | 20.46 |
Price/Earnings
TAK
4568
4519
Financial Strength
|
Metric
|
TAK
|
4568
|
4519
|
|---|---|---|---|
Quick Ratio | 0.54 | 1.76 | 3.43 |
Current Ratio | 1.14 | 2.92 | 4.35 |
Interest Coverage | 0.07 | 22.29 | 9,780.06 |
Quick Ratio
TAK
4568
4519
Profitability
|
Metric
|
TAK
|
4568
|
4519
|
|---|---|---|---|
Return on Assets (Normalized) | 5.53% | 6.65% | 20.24% |
Return on Equity (Normalized) | 11.34% | 15.19% | 23.96% |
Return on Invested Capital (Normalized) | 7.74% | 11.32% | 23.96% |
Return on Assets
TAK
4568
4519
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|ZDppsdB | LOCK|&K?^ | $71B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|rN>tJ!$J | LOCK|T^Ykq | $47B | |||
| Haleon PLC ADR
HLN
| LOCK|#Df&VQ | LOCK|?! | $45B | |||
| Zoetis Inc Class A
ZTS
| LOCK|mH<kLZz | LOCK|Y@ | $34B | |||
| Viatris Inc
VTRS
| LOCK|d%@htP | LOCK|St | $21B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|<@ | LOCK|%#l | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|>^CdlZ | LOCK|gr | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|sjWk&N | LOCK|&X | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|H@g@GJ | LOCK|lxDr | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|vmCym$q | LOCK|dkL | $2B |
United States